All‐cause mortality
Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).
Intervention not reported
All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).
1 finding from 1 review
All‐cause mortality short‐term · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes all‐cause mortality short‐term compared with moderate NMB (very low certainty).
1 finding from 1 review
Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
2 findings from 1 review
Short‐term all‐cause mortality · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial leads to lower short‐term all‐cause mortality compared with transfemoral approach (high certainty).
1 finding from 1 review
All‐cause short‐term mortality · people with unexplained recurrent syncope
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
All‐cause mortality ‐ short term · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment changes all‐cause mortality ‐ short term compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short‐term · health problem or population
It is very uncertain whether summary of findings table ‐ Psychological treatment changes all‐cause mortality ‐ short‐term compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short‐term · Anyone diagnosed with AMI
Cells showed no clear difference in all‐cause mortality ‐ short‐term compared with no cells (moderate certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with low cardiac output syndrome
It is very uncertain whether enoximone changes all‐cause short‐term mortality: 1 month compared with dobutamine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 1 month · adults with cardiogenic shock or low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: time in hospital · adults with low cardiac output syndrome
It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short term (end of treatment) · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment 1 changes all‐cause mortality ‐ short term (end of treatment) compared with pharmacological treatment 2 (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).
1 finding from 1 review